X4 Pharmaceuticals (XFOR) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

XFOR X4 Pharmaceuticals

Watchlist

0.350
-0.010-2.83%

Trading Mar 4 09:42 ET

59.69MMarket Cap-4.38P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

X4 Pharmaceuticals, Taiba to Distribute Xolremdi in Select Middle East Countries
MT NewswiresFeb 19 10:53 ET
Express News | X4 Pharmaceuticals and Taiba Rare Announce Exclusive Agreement for the Distribution and Commercialization of Xolremdi® (Mavorixafor) in Whim Syndrome in Select Middle East Countries
ReutersFeb 19 07:35 ET
Insider Purchase: Chief Commercial Officer of $XFOR Buys 13,404 Shares
Quiver QuantitativeFeb 14 16:18 ET
X4 Pharmaceuticals Analyst Ratings
BenzingaFeb 7 07:37 ET · Ratings
Piper Sandler Maintains X4 Pharmaceuticals(XFOR.US) With Buy Rating, Maintains Target Price $2
Moomoo NewsFeb 7 07:31 ET · Ratings
Analysts Offer Insights on Healthcare Companies: Illumina (ILMN), X4 Pharmaceuticals (XFOR) and IQVIA Holdings (IQV)
TipRanksFeb 7 06:50 ET · Ratings

Comments

Trytosaveabit

15 hours ago

New 8K. Update.

$X4 Pharmaceuticals (XFOR.US)$ Item 8.01 Other Events.
As previously disclosed on a Current Report on Form 8-K filed by X4 Pharmaceuticals, Inc. (the “Company”), on August 13, 2024, the Company received a deficiency letter (the “Nasdaq Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 32 consecutive business days, the closing bid price of the Company’s shares of common stock, $0.001 par value per share (“Common Stock”), has not been maint...

Tonyco

Feb 26 15:33

$X4 Pharmaceuticals (XFOR.US)$
Reduced TAM to about 500 patients in the US (still probably an over-estimate given its rarity) recently. 23-27% of sales face exposure to Rx tariffs. $112M C&E acts as an immediate buffer. Sales targets will likely be lower than projections.

$X4 Pharmaceuticals (XFOR.US)$ X4 Pharmaceuticals And Taiba Rare Partner For XOLREMDI Distribution In Middle East Countries
X4 Pharmaceuticals (XFOR) and taiba rare, a healthcare company, announced a strategic exclusive partnership for the distribution and commercialization of XOLREMDI in select Middle East countries, pending regulatory approvals.

Trytosaveabit

Feb 19 06:44

news

$X4 Pharmaceuticals (XFOR.US)$ Reuters
5 mins ago
X4 Pharmaceuticals and Taiba Rare Announce Exclusive Agreement for the Distribution and Commercialization of Xolremdi® (Mavorixafor) in Whim Syndrome in Select Middle East Countries

XFOR X4 Pharmaceuticals

Trade Overview

Capital Trend

News

Comments

Trending Stocks